Dimerix Limited

DXB

AU000000DXB7

Biotechnology & Medical Research

Market Closed - Australian S.E. 01:16:45 2026-10-23 am EDT			5-day change	1st Jan Change
0.1950 ^AUD	-4.88%		-11.36%	-64.55%

Oct. 22	Dimerix Says Independent Data Supports Investigational Therapy for Kidney Disease; Shares Down 5%	MT
Oct. 18	Dimerix Chair to Retire	MT

Dimerix Appoints CFO

Published on 01/20/2026 at 05:24 pm EST

MT Newswires

This article is reserved for our members.

Continue with Google Continue with Apple Continue with LinkedIn

or by email

Continue with an email.

Latest news about Dimerix Limited

Oct. 22	Dimerix Says Independent Data Supports Investigational Therapy for Kidney Disease; Shares Down 5%	MT
Oct. 18	Dimerix Chair to Retire	MT
Oct. 18	Dimerix Limited Announces Board Changes, Effective October 30, 2026	CI
Oct. 15	Dimerix Says First 100 Patients Enrolled in Phase 3 Kidney Disease Clinical Trial Complete Two-Year Double-Blind Treatment Period	MT
Oct. 04	Dimerix Says First Patient Completes Four Years in Clinical Program for Kidney Disease Drug Candidate; Shares Rise 7%	MT
Sep. 22	Dimerix Receives AU$17 Million in Proceeds After Completing Initial Drawdown Under Non-Dilutive Funding Facility	MT
Sep. 20	Dimerix Limited(ASX:DXB) dropped from S&P/ASX All Ordinaries Index	CI
Sep. 13	Dimerix Says Mexican Composition of Matter Patent Granted for Drug Candidate	MT
Sep. 03	Dimerix Reaches Major Milestone With AU$34 Million Non-Dilutive Loan Facility, Euroz Hartleys Says	MT
Sep. 03	Dimerix Secures AU$34 Million in Non-Dilutive Loan Facility Agreements; Shares Up 4%	MT
Aug. 27	Dimerix Limited Reports Earnings Results for the Full Year Ended June 30, 2026	CI
Aug. 19	Dimerix Receives Initial $10 Million Upfront Payment Under Everest Medicines License Deal; Shares Gain 4%	MT
Aug. 16	Dimerix Completes Transfer of Acute Kidney Injury Drug Candidate's US Investigational New Drug Application, Shares Up 6%	MT
Jul. 22	Dimerix Secures US Patent Regarding Kidney Injury Drug Candidate, Shares Jump 4%	MT
Jul. 17	Dimerix Limited and Mission Therapeutics Limited Expand Pipeline with Acquisition of Phase 2 Ready Asset for Acute Kidney Injury	CI

Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company focused on developing new therapies for kidney diseases. The Company's lead program, DMX-200, is in Phase III clinical development for focal segmental glomerulosclerosis (FSGS), a serious and life-threatening rare kidney disease with limited treatment options. In addition, it is advancing a Phase II program in acute kidney injury (AKI), further strengthening its pipeline in high-need renal indications. DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. The Company's DMX-652 is a selective inhibitor of USP30 - a mitochondrial enzyme that slows the removal of damaged mitochondria. The Phase II trial is designed to investigate DMX-652's potential to prevent kidney injury and preserve renal function. It is also developing DMX-700 for respiratory disease.

Employees

Sector

Biotechnology & Medical Research

More about the company